Adding targeted radiation to standard prostate cancer treatment

This trial is testing whether adding a specialized radiation therapy called SABR (stereotactic ablative radiation therapy) to standard prostate cancer treatment can help patients whose cancer has spread to a few other sites in the body. All patients in the study will receive the standard combination of systemic therapy (medication to fight cancer throughout the body) and radiation to the prostate. Half will also receive this targeted radiation to the areas where cancer has spread, and the other half will receive just the standard treatment.

Doctors want to know if focusing additional radiation directly on tumors that have spread to other parts of the body—in addition to standard treatment—can improve how well the treatment works and reduce cancer recurrence. This medication combination is already standard care, but adding this extra radiation step is newer and not yet proven for this specific patient group.